Session 2: Neurology Breakthroughs
-
Register
- Non-member - $200
- Faculty Member - Free!
Delve into the latest research and therapeutic innovations in neurology, covering advancements in deep brain stimulation, neuroimaging biomarkers, and emerging therapies for neurological disorders.
-
Contains 2 Component(s)
This presentation reviews emerging therapies for multiple sclerosis (MS), focusing on novel treatment approaches beyond disease-modifying agents. We discuss the potential of remyelination strategies, neuroprotective therapies, and immune-modulating agents in slowing disease progression and improving clinical outcomes for MS patients.
This presentation reviews emerging therapies for multiple sclerosis (MS), focusing on novel treatment approaches beyond disease-modifying agents. We discuss the potential of remyelination strategies, neuroprotective therapies, and immune-modulating agents in slowing disease progression and improving clinical outcomes for MS patients.
David Johnson, PhD
Physician
Massachusetts General Hospital
Dr. David Johnson is an internationally recognized expert in medical oncology and translational cancer research. With over 25 years of clinical and academic experience, he has led groundbreaking studies in precision oncology, immunotherapy, and molecular diagnostics. Dr. Johnson earned his medical degree from Stanford University and completed his residency and fellowship at MD Anderson Cancer Center, where he also earned a PhD in Molecular Biology. Currently serving as Chief Medical Officer at Summit Cancer Institute, Dr. Johnson oversees advanced clinical programs that integrate genomic profiling and data-driven treatment pathways. He is best known for pioneering several biomarker-driven clinical trials that have reshaped treatment algorithms in colorectal and lung cancers. His work has been published in leading journals such as The New England Journal of Medicine, JAMA Oncology, and Nature Medicine. Beyond his research and leadership roles, Dr. Johnson is a sought-after speaker and educator, having presented at ASCO, ESMO, and AACR. He also serves on the editorial boards of multiple oncology publications and advisory panels for the FDA and NIH. Dr. Johnson is passionate about advancing health equity in cancer care and mentoring the next generation of physician-scientists.
Jennifer Smith, PhD
Physician
Massachusetts General Hospital
-
Contains 2 Component(s)
This presentation explores the role of neuroimaging biomarkers in the early detection and diagnosis of Alzheimer's disease. We discuss advanced imaging techniques such as PET-CT, MRI, and amyloid imaging, and their utility in identifying preclinical and prodromal stages of Alzheimer's disease.
This presentation explores the role of neuroimaging biomarkers in the early detection and diagnosis of Alzheimer's disease. We discuss advanced imaging techniques such as PET-CT, MRI, and amyloid imaging, and their utility in identifying preclinical and prodromal stages of Alzheimer's disease.
-
Contains 2 Component(s)
This course explores practical strategies for translating evidence-based research into meaningful clinical improvements that enhance patient outcomes, support care teams, and create sustainable change within healthcare organizations.
Introduction: Cardiovascular disease remains a leading cause of morbidity and mortality, yet many modifiable risk factors can be identified before symptoms develop. Routine assessment of blood pressure, lipid levels, glycemic status, lifestyle factors, and family history provides an opportunity for clinicians to recognize elevated cardiovascular risk and initiate preventive interventions earlier.
Purpose: This quality-improvement initiative evaluated whether implementation of a standardized cardiovascular risk-screening protocol in an outpatient primary care setting could increase identification of patients at elevated risk and improve initiation of appropriate preventive care.
Results: A total of 1,240 adult patients were evaluated using the standardized screening protocol over a six-month period. Twenty-eight percent were identified as having previously unrecognized moderate-to-high cardiovascular risk. Among these patients, 72% received a documented lifestyle intervention, medication adjustment, additional diagnostic testing, or referral for follow-up care. Documentation of cardiovascular risk assessment increased from 46% before implementation to 87% following implementation of the protocol.
Conclusion: Standardized cardiovascular risk screening can help clinicians identify patients who may benefit from earlier preventive intervention. Incorporating structured risk assessment into routine care improved documentation and increased initiation of evidence-based preventive strategies. Early identification and management of cardiovascular risk factors may ultimately reduce preventable cardiovascular events and improve long-term patient outcomes.- Identify key modifiable and non-modifiable risk factors associated with cardiovascular disease.
- Describe the role of standardized cardiovascular risk screening in identifying patients who may benefit from early intervention.
- Apply evidence-based cardiovascular risk assessment strategies within routine clinical practice.
- Evaluate appropriate preventive interventions for patients identified as having moderate-to-high cardiovascular risk.
- Develop strategies for incorporating structured cardiovascular risk assessment and follow-up into outpatient care workflows.
Emily Chen, MD, MPH, FACC
Associate Professor of Cardiology
Mid-Atlantic University Medical Center
Emily Chen is a healthcare professional and educator with a passion for advancing patient care through evidence-based practice and clinical innovation. Her work focuses on helping healthcare teams translate research, data, and emerging best practices into practical strategies that improve outcomes and strengthen the patient experience. Emily is particularly interested in interdisciplinary collaboration, sustainable quality improvement, and the thoughtful adoption of new clinical processes and technologies. Through her educational work, she aims to provide healthcare professionals with actionable tools they can apply within their own organizations.